Overview

A Study to Evaluate Efficacy and Safety of GW117 Tablets in Major Depressive Disorder

Status:
COMPLETED
Trial end date:
2023-10-12
Target enrollment:
Participant gender:
Summary
The study aims to evaluate the efficacy and safety of GW117 Tablets compared to placebo in adults participants with MDD over a period of 8 weeks.
Phase:
PHASE2
Details
Lead Sponsor:
Beijing Greatway Pharmaceutical Technology Co.,Ltd.
Treatments:
GW117